JP2004518659A - 新規ｓＰＬＡ２インヒビター - Google Patents

新規ｓＰＬＡ２インヒビター Download PDF

Info

Publication number
JP2004518659A
JP2004518659A JP2002551531A JP2002551531A JP2004518659A JP 2004518659 A JP2004518659 A JP 2004518659A JP 2002551531 A JP2002551531 A JP 2002551531A JP 2002551531 A JP2002551531 A JP 2002551531A JP 2004518659 A JP2004518659 A JP 2004518659A
Authority
JP
Japan
Prior art keywords
group
acid
compound
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002551531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004518659A5 (enExample
Inventor
ダグラス・ウェイド・ベイト
マイケル・ディーン・キニック
ホ−シェン・リン
ジョン・マイケル・モリン・ジュニア
マイケル・エンリコ・リチェット
ダニエル・ジョン・ソール
ジェイソン・スコット・ソーヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2004518659A publication Critical patent/JP2004518659A/ja
Publication of JP2004518659A5 publication Critical patent/JP2004518659A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
JP2002551531A 2000-12-18 2001-12-06 新規ｓＰＬＡ２インヒビター Pending JP2004518659A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25639600P 2000-12-18 2000-12-18
PCT/US2001/043185 WO2002050034A2 (en) 2000-12-18 2001-12-06 Tetracyclic carbazole derivates and their use as spla2 inhibitors

Publications (2)

Publication Number Publication Date
JP2004518659A true JP2004518659A (ja) 2004-06-24
JP2004518659A5 JP2004518659A5 (enExample) 2005-12-22

Family

ID=22972091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002551531A Pending JP2004518659A (ja) 2000-12-18 2001-12-06 新規ｓＰＬＡ２インヒビター

Country Status (6)

Country Link
US (1) US6872743B2 (enExample)
EP (1) EP1345898A2 (enExample)
JP (1) JP2004518659A (enExample)
AU (1) AU2002239263A1 (enExample)
CA (1) CA2431028A1 (enExample)
WO (1) WO2002050034A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992100B2 (en) * 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
WO2007032854A1 (en) * 2005-08-19 2007-03-22 Schering Corporation FUSED TRICYCLIC mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS
EP2240481A1 (en) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503055A (ja) 1996-10-30 2001-03-06 イーライ・リリー・アンド・カンパニー 置換三環化合物群
DZ2769A1 (fr) 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
AU2002239263A1 (en) 2002-07-01
WO2002050034A3 (en) 2003-01-16
WO2002050034A2 (en) 2002-06-27
CA2431028A1 (en) 2002-06-27
EP1345898A2 (en) 2003-09-24
US6872743B2 (en) 2005-03-29
US20040063941A1 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
AU753547B2 (en) Substituted tricyclics
JP2004518658A (ja) 新規なｓＰＬＡ２インヒビター
JP2004518659A (ja) 新規ｓＰＬＡ２インヒビター
JP2004518659A5 (enExample)
JP2005527464A (ja) ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
EP1438290B1 (en) Cyclohept b!indole derivatives as spla2 inhibitors
CA2356159A1 (en) Novel spla2 inhibitors
JP2004505982A (ja) 新規なｓＰＬＡ２インヒビター
EP1202963A1 (en) Spla2 inhibitors
EP1395554A1 (en) Substituted carbazoles as inhibitors of spla2
EP1349836B1 (en) Tetracyclic derivatives as spla2 inhibitors
US20040092543A1 (en) Novel spla2 inhibitors
JP2004518657A (ja) 新規なｓＰＬＡ２インヒビター
JP2004520363A (ja) 新規なｓＰＬＡ２インヒビター
JP2003509491A (ja) 新規なｓＰＬＡ２インヒビター
EP1248769A2 (en) Carbazole derivatives as inhibitors of spla2
JP2004501910A (ja) 新規なｓＰＬＡ２インヒビター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106